I think the termination of the Incline agreement is the best choice. CADX must focus on their own product versus expansion right now. They get some cash from the opt out deal and Medicines is better positioned for Incline support anyway.
The facts are CADX is more likely to be bought than doing any buying at this point where they stand! Maybe Medicines will absorb CADX down the road based on their core assets in-house in hospitals!
The goal is cash flow positive ASAP---I say next year some time!